Beyhan Durak Aras1, Sevgi Isik2, Hava Uskudar Teke3, Abdulvahap Aslan4, Filiz Yavasoglu5, Zafer Gulbas6, Fatih Demirkan7, Hulya Ozen8, Oguz Cilingir2, Nur Sena Inci2, Gulcin Gunden2, Tuba Bulduk3, Ebru Erzurumluoglu Gokalp2, Sinem Kocagil2, Sevilhan Artan2, Olga Meltem Akay9. 1. Department of Medical Genetics, Faculty of Medicine, University of Eskisehir Osmangazi, Professor Dr. Nabi Avcı Street, No. 4, Eskisehir, Buyukdere, 26040, Turkey. bdurak@ogu.edu.tr. 2. Department of Medical Genetics, Faculty of Medicine, University of Eskisehir Osmangazi, Professor Dr. Nabi Avcı Street, No. 4, Eskisehir, Buyukdere, 26040, Turkey. 3. Department of Hematology, Faculty of Medicine, University of Eskisehir Osmangazi, Eskisehir, Turkey. 4. Department of Hematology, Private Umit Hospital, Eskisehir, Turkey. 5. Department of Hematology, Faculty of Medicine, University of Afyonkarahisar Health Sciences, Afyon, Turkey. 6. Department of Hematology, Anadolu Medical Center, Kocaeli, Turkey. 7. Department of Oncology, Faculty of Medicine, University of Dokuz Eylul, Izmir, Turkey. 8. Department of Biostatistics, Faculty of Medicine, University of Eskisehir Osmangazi, Eskisehir, Turkey. 9. Department of Hematology, Faculty of Medicine, University of Koc, Istanbul, Turkey.
Abstract
BACKGROUND: Deletion of 13q14 [del(13q)] is the most common cytogenetic change (50%) in chronic lymphoblastic leukemia (CLL), and it is a good prognostic factor if it is detected as a sole aberration by FISH. However, it is observed the clinical course of CLL cases with del(13q) are quite heterogeneous and the responsible for this clinical heterogeneity has not been established yet. Some investigators suggest type II deletion (include RB1 gene) is associated with more aggressive clinical course. Also, it is suggested that the deletion burden and the deletion type have a prognostic effect. In this study, we aimed to investigate the effect of RB1 gene deletion, deletion burden and deletion type on overall survival (OS), disease stage and time to first treatment (TTFT) in patients with isolated del(3q). Sixty eight cases, detected isolated del(13q) were included in the study. Also, RB1 deletion was analyzed from peripheral blood of them using FISH. RESULTS: RB1 deletion was detected in 41% of patients, but there was no statistically significant difference between RB1 deletion and TTFT, stage and OS (p > 0.05). At same time, statistically significant difference was detected between high del(13q) (> 80%) and TTFT (p < 0.05). CONCLUSION: The statistical analysis of our data regarding to the association between RB1 deletion and deletion type, TTFT, disease stage, and OS has not confirmed type II deletion or biallelic deletion cause poor prognosis. However, our data supports the deletion burden has a prognostic effect. More studies are needed to elucidate the cause of the clinical heterogeneity of CLL cases with del(13q).
BACKGROUND: Deletion of 13q14 [del(13q)] is the most common cytogenetic change (50%) in chronic lymphoblastic leukemia (CLL), and it is a good prognostic factor if it is detected as a sole aberration by FISH. However, it is observed the clinical course of CLL cases with del(13q) are quite heterogeneous and the responsible for this clinical heterogeneity has not been established yet. Some investigators suggest type II deletion (include RB1 gene) is associated with more aggressive clinical course. Also, it is suggested that the deletion burden and the deletion type have a prognostic effect. In this study, we aimed to investigate the effect of RB1 gene deletion, deletion burden and deletion type on overall survival (OS), disease stage and time to first treatment (TTFT) in patients with isolated del(3q). Sixty eight cases, detected isolated del(13q) were included in the study. Also, RB1 deletion was analyzed from peripheral blood of them using FISH. RESULTS:RB1 deletion was detected in 41% of patients, but there was no statistically significant difference between RB1 deletion and TTFT, stage and OS (p > 0.05). At same time, statistically significant difference was detected between high del(13q) (> 80%) and TTFT (p < 0.05). CONCLUSION: The statistical analysis of our data regarding to the association between RB1 deletion and deletion type, TTFT, disease stage, and OS has not confirmed type II deletion or biallelic deletion cause poor prognosis. However, our data supports the deletion burden has a prognostic effect. More studies are needed to elucidate the cause of the clinical heterogeneity of CLL cases with del(13q).
Authors: H Parker; M J J Rose-Zerilli; A Parker; T Chaplin; R Wade; A Gardiner; M Griffiths; A Collins; B D Young; D G Oscier; J C Strefford Journal: Leukemia Date: 2010-12-10 Impact factor: 11.528
Authors: Tait D Shanafelt; Thomas E Witzig; Stephanie R Fink; Robert B Jenkins; Sarah F Paternoster; Stephanie A Smoley; Kimberly J Stockero; Danielle M Nast; Heather C Flynn; Renee C Tschumper; Susan Geyer; Clive S Zent; Tim G Call; Diane F Jelinek; Neil E Kay; Gordon W Dewald Journal: J Clin Oncol Date: 2006-10-01 Impact factor: 44.544
Authors: Peter Ouillette; Harry Erba; Lisa Kujawski; Mark Kaminski; Kerby Shedden; Sami N Malek Journal: Cancer Res Date: 2008-02-15 Impact factor: 12.701
Authors: Katy Hanlon; Sian Ellard; Claudius E Rudin; Susan Thorne; Teresa Davies; Lorna W Harries Journal: J Mol Diagn Date: 2009-05-21 Impact factor: 5.568
Authors: José Angel Hernández; Ana Eugenia Rodríguez; Marcos González; Rocío Benito; Celia Fontanillo; Virgilio Sandoval; Mercedes Romero; Guillermo Martín-Núñez; Alfonso García de Coca; Rosa Fisac; Josefina Galende; Isabel Recio; Francisco Ortuño; Juan Luis García; Javier de las Rivas; Norma Carmen Gutiérrez; Jesús F San Miguel; Jesús María Hernández Journal: Haematologica Date: 2009-03 Impact factor: 9.941